share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

SEC ·  Aug 24 05:27
Summary by Futu AI
Recursion Pharmaceuticals, Inc. CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/23/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 737,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.
Recursion Pharmaceuticals, Inc. CEO Christopher Gibson acquired 5,000 shares of the company's Class A Common Stock on 08/23/2024. The transaction was executed at a price of $2.48 per share, indicating a total investment of $12,400. Following this purchase, Gibson's direct holdings in the company increased to 737,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.